Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Huntington National Bank

Huntington National Bank raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 277,377 shares of the medical equipment provider’s stock after purchasing an additional 10,806 shares during the period. Intuitive Surgical accounts for approximately 1.0% of Huntington National Bank’s holdings, making the stock its 21st biggest position. Huntington National Bank’s holdings in Intuitive Surgical were worth $136,267,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ISRG. Ridgewood Investments LLC bought a new stake in shares of Intuitive Surgical during the 2nd quarter worth about $26,000. Godsey & Gibb Inc. raised its position in shares of Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares in the last quarter. Creekmur Asset Management LLC raised its position in shares of Intuitive Surgical by 200.0% during the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 42 shares in the last quarter. LGT Financial Advisors LLC raised its position in shares of Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 54 shares in the last quarter. Finally, Delos Wealth Advisors LLC raised its position in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 57 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $536.69 on Thursday. The firm has a market cap of $191.16 billion, a price-to-earnings ratio of 86.28, a price-to-earnings-growth ratio of 5.28 and a beta of 1.39. The stock’s 50-day moving average is $495.85 and its 200-day moving average is $455.08. Intuitive Surgical, Inc. has a one year low of $287.98 and a one year high of $542.59.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The company had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. On average, equities analysts expect that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

Insider Buying and Selling

In other Intuitive Surgical news, insider Jamie Samath sold 22,903 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the transaction, the insider now owns 8,757 shares of the company’s stock, valued at $4,597,425. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jamie Samath sold 22,903 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $525.00, for a total value of $12,024,075.00. Following the sale, the insider now directly owns 8,757 shares in the company, valued at $4,597,425. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 91,178 shares of company stock worth $45,897,071. Corporate insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on ISRG. Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a report on Friday, October 18th. Evercore ISI reiterated a “cautious” rating on shares of Intuitive Surgical in a report on Friday, October 18th. JPMorgan Chase & Co. boosted their target price on shares of Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, Stifel Nicolaus boosted their target price on shares of Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.